trending Market Intelligence /marketintelligence/en/news-insights/trending/jmti2vgfnghxeiyjt63pla2 content esgSubNav
In This List

VBI Vaccines launches common stock offering


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

VBI Vaccines launches common stock offering

VBI Vaccines Inc. started an underwritten public offering of its common shares.

The company plans to grant the underwriters a 30-day option to buy up to an additional 15% of the number of common shares offered in the public offering.

Net proceeds will be used to advance the company's research and development programs, including funding the pivotal phase 3 clinical program for Sci-B-Vac in the U.S., Europe and Canada; funding the phase 1/2a clinical study of VBI-1901 for glioblastoma; funding VBI-1501, VBI's cytomegalovirus vaccine candidate; and funding VBI-2601, the company's immuno-therapeutic candidate for hepatitis B.

Net proceeds will also be used for general corporate purposes, including working capital and capital expenditures.

BMO Capital Markets, Canaccord Genuity LLC and Oppenheimer & Co. Inc. are acting as joint book-runners for the offering.

VBI Vaccines is a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines.